EGFR and non-small cell lung carcinoma: Interestingly, the randomized ECOG-ACRIN 1512 phase II study in pretreated EGFR wild type NSCLC patients demonstrated a doubling of PFS with cabozantinib/erlotinib compared to erlotinib alone, (4.7 v 1.8 months, HR 0.37, 95% CI 0.25-0.53, one-sided p=0.0003) [24].